Development of hepatotoxicity in HIV patients switching at least one protease inhibitor
| Autor: | Aceti, Antonio, Pasquazzi, Caterina, Zechini, B., De Bac, C., Liverhaart Group, T. H. E. |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Sexually transmitted disease hepatotoxicity medicine.medical_specialty hepatitis virus protease inhibitors HIV Infections hiv Dermatology Gastroenterology art Internal medicine Immunopathology medicine Humans Pharmacology (medical) Protease inhibitor (pharmacology) Retrospective Studies biology business.industry Public Health Environmental and Occupational Health Alanine Transaminase HIV Protease Inhibitors Middle Aged Hepatitis B medicine.disease Hepatitis C Infectious Diseases Liver Alanine transaminase Toxicity Immunology biology.protein Female Ritonavir Viral disease Viral hepatitis business medicine.drug |
| Zdroj: | International Journal of STD & AIDS. 16:148-152 |
| ISSN: | 1758-1052 0956-4624 |
| DOI: | 10.1258/0956462053057585 |
| Popis: | In order to evaluate the occurrence of hepatotoxicity in patients treated with antiretroviral therapy (ART) who switch protease inhibitor (PI), and the role of viral hepatitis in its development, we performed a retrospective study on 182 HIV patients treated with ART for 24 months. The presence of hepatitis viruses and alanine transaminase levels were evaluated. Hepatotoxicity developed in a low number of subjects without co-infection, but was significantly higher in co-infected patients (14/51 versus 62/131, P = 0.01). Ritonavir was associated with higher rates of severe hepatotoxicity in the co-infected group. Patients presenting any problems related to ART, including the development of hepatotoxicity, continued therapy by switching PI. The occurrence of hepatotoxicity with second/third choice PIs, including ritonavir, remained stable. Our results suggest that switching PI does not increase the occurrence of drug-related liver toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|